Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint-Inhibitor-Naive Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy

NCT03558139 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03558139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03558139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint-Inhibitor-Naive Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Completed
Start date
May 23, 2018
Completion date
December 3, 2020
Enrollment
34 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer